1. 1) Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm., 235, 179–192 (2002).
2. 2) Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med., 18, 1639–1642 (2012).
3. 3) Araki T, Kono Y, Ogawara K, Watanabe T, Ono T, Kimura T, Higaki K. Formulation and evaluation of paclitaxel-loaded polymeric nanoparticles composed of polyethylene glycol and polylactic acid block copolymer. Biol. Pharm. Bull., 35, 1306–1313 (2012).
4. 4) Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, Rose PG. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol. Oncol., 96, 10–18 (2005).
5. 5) Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res., 11, 4136–4143 (2005).